Learning Objectives
Upon completion of this activity, participants should be better able to:
- Explain the relevance of achieving cytogenetic and molecular remission following therapy for CML with respect to progression-free survival and overall survival
- Identify the methods used to assess molecular remission and their level of sensitivity in detecting minimal residual disease
- Explain the mechanisms of imatinib mesylate resistance and the novel strategies developed to overcome this resistance
- Describe the options available for imatinib mesylate-resistant or -relapsing disease and their rationale for use in CML
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Curatio CME Institute and Carden Jennings Publishing. Curatio CME Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Curatio CME Institute designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure
Curatio CME Institute adheres to ACCME Essential Areas, Standards for Commercial Support, and Policies regarding industry support of continuing medical education. Disclosure of the commercial relationships of everyone in a position to control content of an educational activity will be made at the activity. Speakers are also required to openly disclose discussion of any off-label, experimental,or investigational use of drugs or devices in their presentations.
Faculty
Francis J. Giles, MB, MD, FRCPI, FRCPath
Professor of Medicine
Chief, Division of Hematology and Medical Oncology
University of Texas Health Science Center at San Antonio.
Director and AT&T Chair, Institute for Drug Development
Cancer Therapy & Research Center
San Antonio, Texas
Michael J. Mauro, MD
Associate Professor of Medicine
Division of Hematology & Medical Oncology
Oregon Health Science University
Portland, Oregon
Jerald P. Radich, MD
Member of the Clinical Research Division
Fred Hutchinson Cancer Research Center
Professor of Medicine, Division of Oncology
University of Washington School of Medicine
Seattle, Washington
Moshe Talpaz, MD
Professor, Department of Internal Medicine
Associate Director of Translational Research
Associate Chief/Director of Hematologic Malignancies
University of Michigan Cancer Center
Ann Arbor, Michigan
Faculty Disclosures
In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
- Dr. Francis Giles: research support from Amgen, Bristol-Myers Squibb, Merck, Novartis, and Pfizer.
- Denise C. LaTemple, PhD, Vice President, Scientific Services, Curatio CME Institute: No relevant financial relationships.
- Dr. Michael J. Mauro: research support from Bristol-Myers Squibb; speakers bureau for Bristol-Myers Squibb and Novartis.
- Dr. Jerald P. Radich: research support from and consultant for Bristol-Myers Squibb and Novartis.
- Dr. Moshe Talpaz: research support, consultant, and speakers bureau for Bristol-Myers Squibb and Novartis.
Method of Participation
There are no fees for participating in this CME activity. To receive credit during the period April 2008 to April 30, 2009, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, (3) complete the posttest, and (4) complete the activity evaluation form, including the certificate information section.
The posttest can be accessed at the end of the activity. Please e-mail any questions to
This email address is being protected from spam bots, you need Javascript enabled to view it
Medium
The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.
Disclaimer
The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient's medical condition.
Privacy Policy
Curatio CME Institute collects the information provided by the user. The information is used to provide notification about upcoming programs and educational information that may be of interest to our users. The information is not shared with others for commercial purposes, unless prior permission has been granted by the user.
Curatio CME Institute may collect standard Web traffic data such as the time and date of visit. Curatio CME Institute uses this information to administer its Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Curatio CME Institute does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Curatio CME Institute does, when required, provide the minimum subset of information to third parties that are responsible for accreditation and issuance of certification of CME/CE tests submitted. By participating in the Web-based activity, you agree that Curatio CME Institute has full permission to provide this minimum subset of information to third parties as required by law.
For CME questions, please contact
This email address is being protected from spam bots, you need Javascript enabled to view it
or call (610)363-1619 ext. 113. If you experience technical difficulties, please contact
This email address is being protected from spam bots, you need Javascript enabled to view it
RSS / Subscribe
Release date: April 2008
